Page 11 - Read Online

Komiya et al. J Cancer Metastasis Treat 2018;4:1 Journal of Cancer
DOI: 10.20517/2394-4722.2017.65 Metastasis and Treatment

Original Article Open Access

Impact of previous anti-angiogenesis treatment in
nivolumab-treated advanced non-small cell lung

cancer

Takefumi Komiya , Chao H. Huang , Prakash Neupane , Stephen K. Williamson , Prabhakar Chalise 3
2
1,2
2
2
1 Section of Hematology/Oncology, Tulane University School of Medicine, New Orleans, LA 70112, USA.
2 Division of Medical Oncology, University of Kansas Medical Center, Fairway, KS 66205, USA.
3 Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS 66160, USA.
Correspondence to: Dr. Takefumi Komiya, Section of Hematology/Oncology, Tulane University School of Medicine,1430 Tulane
Ave, #8078, New Orleans, LA 70112, USA. E-mail: tkomiya@tulane.edu

How to cite this article: Komiya T, Huang CH, Neupane P, Williamson SK, Chalise P. Impact of previous anti-angiogenesis
treatment in nivolumab-treated advanced non-small cell lung cancer. J Cancer Metastasis Treat 2018;4:1.
http://dx.doi.org/10.20517/2394-4722.2017.65
Received: 18 Nov 2017 First Decision: 25 Dec 2017 Revised: 27 Dec 2017 Accepted: 3 Jan 2018 Published: 17 Jan 2018

Science Editor: Lombardi Giuseppe Copy Editor: Lu Liu Production Editor: Cai-Hong Wang

Abstract

Aim: To investigate how previous systemic therapy such as anti-angiogenesis can influence cancer immunotherapy for
non-small cell lung cancer (NSCLC).

Methods: A total of 134 patients with advanced NSCLC who were treated with nivolumab were retrospectively reviewed.
Correlation between status of prior anti-angiogenesis treatment and clinical characteristics were determined. Impact of
prior anti-angiogenesis on therapeutic outcome of nivolumab was investigated for tumor efficacy such as progression-
free survival (PFS).

Results: Sixteen patients were treated with at least one anti-angiogenesis agent prior to nivolumab. The prior use of anti-
angiogenesis agent was associated with stage IV disease, non-squamous histology, and two or more lines of systemic
therapy. Median PFS was significantly shorter in the prior anti-angiogenesis group than in no prior anti-angiogenesis
group (8.3 vs. 11.3 weeks, log-rank P = 0.006). Multivariate analyses demonstrated that only prior anti-angiogenesis
status was associated with worse PFS. There is also a slight trend for worse disease control rate (P = 0.101, Fisher’s exact
test) and overall survival (P = 0.200, log-rank) in prior anti-angiogenesis group.

Conclusion: This retrospective study suggests that prior anti-angiogenesis treatment negatively impacts the therapeutic
outcome of immunotherapy in advanced NSCLC.

© The Author(s) 2018. Open Access This article is licensed under a Creative Commons Attribution 4.0
International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long
as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license,
and indicate if changes were made.

www.jcmtjournal.com